- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02274610
Pharmacokinetic Study of Docetaxel-PNP and Taxotere to Treat Patient With Advanced Solid Cancer (DOPNP201)
Phase I Trial to Compare Pharmacokinetics and Safety of Docetaxel PNP With Taxotere in Subjects With Advanced Solid Tumor
Study Overview
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Phase 1
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Patient ages more than 18 years old
- Patient should voluntarily sign a written informed consent before study entry
- Patient historically or cytologically confirmed diagnosis of advanced solid tumor and patient with measurable disease or evaluable disease by RECIST criteria
- Progressive disease with development of new lesions or an increase in preexisting lesions or standard therapy in order to provide clinical benefit does not exist or is no longer effective
- Previous anti-cancer therapies must be completed before 21days of first study dose and Patient must have recovered from any previous therapy
- Patient has an Eastern Cooperative Oncology Group (ECOG) Performance Status 0-1
- Patient has a life expectancy of at least 3 months
Baseline studies for determining eligibility must be completed within 14 days of first study dose and patient has a adequate organ function including the following:
- Hb ≥ 10g/dl
- ANC ≥ 1.5 X 109/L
- Platelet count ≥ 100 X 109/L
- Serum total bilirubin ≤ 1.5 mg/dL
- Serum AST and ALT ≤ 2.5 X UNL
- Serum ALP ≤ 2.5ⅹUNL
- Serum creatinine ≤ 1.5 X UNL
Exclusion Criteria:
- Patient has had a major surgery except tumor ablation within 2 weeks before screening visit
- Patient has a brain metastasis with neurologic symptom
- Patient has a sensory neuropathy or motor neuropathy ≥ grade 2 by NCI-CTCAE
- Patient has any serious concurrent disease such as:
Any medical or psychiatric condition that, in the opinion of the investigator, would prohibit the understanding and giving of informed consent Severe cardiovascular disease (e.g. ischemic heart disease requiring medication or myocardial infraction within the past six months, grade 3-4 congestive heart failure defined by the New York Heart Association criteria) Active un controlled infection.
- Patient has hypersensitivity to the Investigational product or their excipients
- Patient has participated in any other clinical trial within 4 weeks before screening visit
- Woman is pregnant or breast feeding
Subjects who are of childbearing potential who do not use a medically acceptable method of birth control or do not agree to continue use of this method throughout the trial (screening, treatment period, and 3 weeks from the last done). A negative pregnancy test (urine or serum) should be documented within 14 days prior to initiation of trial medication for women of childbearing potential who have not been amenorrheic for at least 12 months prior to registration into the trial or surgically sterile (bilateral tubal ligation, bilateral oophorectomy or hysterectomy). Medically acceptable methods include:
- Barrier method with spermicide
- Intrauterine device
- Complete abstinence, etc.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: CROSSOVER
- Masking: NONE
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
EXPERIMENTAL: Group A
Period 1: Docetaxel-PNP / Washout: 3 weeks / Period 2: Taxotere
|
Docetaxel Polymeric Nanoparticle Formulation
Docetaxel
|
EXPERIMENTAL: Group B
Period 1: Taxotere / Washout: 3 weeks / Period 2: Docetaxel-PNP
|
Docetaxel Polymeric Nanoparticle Formulation
Docetaxel
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Pharmacokinetics of DocetaxelPNP and Taxotere in terms of Area Under the Curve (AUC)
Time Frame: 3 months
|
3 months
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Elimination Half Life (T1/2) of DocetaxelPNP and Taxotere
Time Frame: 3 months
|
3 months
|
Clearance (CL) of DocetaxelPNP and Taxotere
Time Frame: 3 months
|
3 months
|
Volume of Distribution at steady state (Vdss) of DocetaxelPNP and Taxotere
Time Frame: 3 months
|
3 months
|
Number of participants with Adverse Events
Time Frame: 3 months
|
3 months
|
Collaborators and Investigators
Investigators
- Study Director: Mi-ryung Jin, Masters, Samyang Biopharmaceuticals Corporation
Study record dates
Study Major Dates
Study Start (ACTUAL)
Primary Completion (ACTUAL)
Study Completion (ACTUAL)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (ESTIMATE)
Study Record Updates
Last Update Posted (ACTUAL)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- DOPNP201
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Solid Tumor
-
Memorial Sloan Kettering Cancer CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Memorial Sloan Kettering Cancer CenterLincoln Medical and Mental Health CenterRecruitingSolid Tumor | Solid Tumor, Adult | Solid Tumor, Unspecified, AdultUnited States, Puerto Rico
-
Aadi Bioscience, Inc.RecruitingAdvanced Solid Tumor | Tumor | Tumor, SolidUnited States
-
Sorrento Therapeutics, Inc.WithdrawnSolid Tumor | Relapsed Solid Tumor | Refractory Tumor
-
RemeGen Co., Ltd.CompletedMetastatic Solid Tumor | Locally Advanced Solid Tumor | Unresectable Solid TumorAustralia
-
Impact Therapeutics, Inc.RecruitingSolid Tumor | Advanced Solid TumorChina, Taiwan, United States, Australia
-
Partner Therapeutics, Inc.WithdrawnSolid Tumor | Solid Tumor, AdultUnited States
-
Shenzhen Ionova Life Sciences Co., Ltd.Merck Sharp & Dohme LLCRecruitingCancer | Solid Tumor, Adult | Solid Carcinoma | Solid Tumor, Unspecified, Adult | Cancer Metastatic | Tumor, SolidUnited States
-
BeiGeneRecruitingSolid Tumor | Advanced Solid TumorUnited States, New Zealand, Australia, China
Clinical Trials on Docetaxel-PNP
-
Samyang Biopharmaceuticals CorporationCompleted
-
Regeneron PharmaceuticalsRecruitingHealthy Volunteers | Non-alcoholic Fatty Liver Disease (NAFLD)United States
-
Vienna Hospital AssociationRecruiting
-
Regeneron PharmaceuticalsNot yet recruitingNonalcoholic Steatohepatitis (NASH) | Nonalcoholic Fatty Liver Disease (NAFLD) | Genetic Risk Factor
-
Rahul AggarwalNovartisCompletedProstate CancerUnited States
-
Nereus Pharmaceuticals, Inc.CompletedCancerUnited States, Australia, India, Chile, Brazil, Argentina
-
Tianjin Medical University Cancer Institute and...Recruiting
-
National Cancer Center, KoreaSeoul National University Bundang Hospital; Gachon University Gil Medical Center and other collaboratorsUnknownGastric CancerKorea, Republic of
-
Zhuhai Beihai Biotech Co., LtdCompletedSolid Tumours | Bioequivalence | DocetaxelIndia
-
Jiangsu HengRui Medicine Co., Ltd.Shanghai Pulmonary Hospital, Shanghai, ChinaCompletedNon-Small Cell Lung Cancer (NSCLC)China